AZ seeks blood test to ID potential patients

Roche and Qiagen are developing a blood test that will help identify patients who would benefit from one of two AstraZeneca lung drugs. Reuters reports that success would mean a simple blood test could replace the need to extract tissue samples, a process which usually requires a needle biopsy or surgery. Reuters says the blood test would use technology that “can detect small fragments of circulating tumor DNA in the plasma.”

The expectation is that the test will be used to identify patients for AstraZeneca's approved lung cancer drug Iressa and for the still-experimental AZD9291, which could be Iressa's successor.

You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.